The Incretin Mimetics
Exenatide clinical efficacy The Phase 3 clinical efficacy studies that have been conducted with exenatide are listed in Table 4.1. Three 30-week, placebo-controlled studies evaluated exenatide (5 µj.g or 10…
Dipeptidyl Peptidase-4 Inhibitors
In a 52-week active-comparator study, patients not achieving adequate glycaemic control on a metformin dose of at least 1500 mg/day were randomized to sitagliptin 100 mg once daily or glipizide,…
Epidemiology and Pathogenesis of Type 2 Diabetes
Related posts: The Incretin System Overview of Current Diabetes Management Bariatric Surgery for the Treatment of Type 2 Diabetes Sodium-glucose Cotransporter-2 Inhibitors Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Sodium-glucose Cotransporter-2 Inhibitors
Figure 6.2 Adjusted mean (95% CI) percent change from baseline in body weight after 12 weeks of dapagliflozin treatment. Reproduced from List et al. (2009) with permission from the American…
Bariatric Surgery for the Treatment of Type 2 Diabetes
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Pipeline Diabetes Therapies
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Organization of Diabetes Care
CHAPTER 9 Organization of Diabetes Care Diabetes is a chronic illness that requires continuing medical care and patient education to prevent acute complications and to reduce the risk of long-term…
Overview of Current Diabetes Management
Related posts: The Incretin System Organization of Diabetes Care Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
The Incretin System
Related posts: Overview of Current Diabetes Management Organization of Diabetes Care Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
